# 5G-EMERALD: Amivantamab in Malignant Brain Tumours

> **NCT06632236** · PHASE1 · RECRUITING · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 12 (estimated)

## Conditions studied

- Malignant Primary Gliomas
- Glioblastoma Multiform (Grade IV Astrocytoma)
- Diffuse Hemispheric Glioma, H3 G34-Mutant
- Glioblastoma Multiforme (GBM)

## Interventions

- **DRUG:** Amivantamab

## Key facts

- **NCT ID:** NCT06632236
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-09
- **Primary completion:** 2026-03-05
- **Final completion:** 2027-03-05
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-04-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06632236

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06632236, "5G-EMERALD: Amivantamab in Malignant Brain Tumours". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06632236. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*